FDA Advisory Vote on Peptides — Full Breakdown & Transcript

[00:09] A regulatory event has just transformed the future of peptide therapy and longevity medicine in the United States. For the past 3 years, clinicians, researchers, and patients interested in using peptides have faced severe

[00:22] using peptides have faced severe restrictions. Back in late 2023, the Food and Drug Administration placed 19 of the most popular therapeutic peptides into category 2, a restricted status that effectively halted traditional

[00:36] compounding pharmacies from legally preparing them for patients. disruption across the health and community, leaving thousands of patients with limited access to therapies that they had relied on for tissue repair,

[00:51] gut health, and metabolic optimization. However, following major policy shifts within Department of Health and Human Services in April 2026, the FDA scheduled a public hearing before its Pharmacy Compounding Advisory

[01:07] Committee, or PCAC. Over 2 days of expert testimony, the advisory panel decided to override the official recommendations of agency staff and voted in favor of six out of seven evaluated peptides.

[01:22] Today, we're going to break down exactly what happened at this meeting, explain what the different regulatory categories mean for compounding, examine the specific peptides evaluated, and explore the crucial next steps for patients and

[01:35] clinicians navigating this evolving landscape. To understand the significance of this meeting, we first need to understand how the FDA regulates compounding pharmacies under section 503A of the Federal Food,

[01:50] Drug, and Cosmetic Act. Traditional compounding pharmacies prepare customized medications prescribed by licensed physicians for individual patients whose medical needs cannot be met by commercially

[02:02] cannot be met by commercially manufactured FDA-approved drugs. Under section 503A, compounding pharmacies are permitted to use bulk drug substances, meaning the raw, pure active pharmaceutical ingredients, if

[02:17] those substances appear on an official codified list known as the bulk drug substances positive list, or if they are components of approved medications, or have a recognized United States Pharmacopoeia monograph.

[02:33] Because the formal process of adding a substance to this positive list can take years, the FDA established an interim policy dividing nominated bulk categories. Category one includes substances

[02:48] nominated with sufficient scientific and clinical information that are currently under formal evaluation. Substances in category one are permitted for compounding under the agency's informal enforcement discretion while

[03:01] the evaluation is underway. Category two consists of substances that the FDA believes raise significant safety concerns. When a substance is placed in category two, it is effectively banned from

[03:14] compounding, and pharmacies that prepare it face direct regulatory enforcement. Category three includes substances nominated without adequate scientific data, which are also not permitted for compounding.

[03:29] For those who are interested in more detail on how the compounding works, I spoke to a person from a compounding agency, and I've linked to that discussion above. In 2023, when the FDA placed peptides

[03:42] In 2023, when the FDA placed peptides like BPC-157 and TB-500 into category they argued that these molecules lacked sufficient large-scale human clinical trial data, and pose potential risks related to immunogenicity, peptide

[03:57] purity, and systemic toxicity. This reclassification effectively pushed these substances out of regulated pharmacies and triggered a massive surge in unregulated black market and gray market online sales.

[04:12] On July 23 and 24, 2026, the PCAC convened to formally evaluate seven nominated peptides for compounding under section 503A.

[04:24] Going into the hearing, agency staff scientists presented formal briefing documents recommending that the committee vote against all seven peptides, citing a lack of traditional randomized double-blind phase three

[04:36] clinical trials demonstrating safety and efficacy. However, the independent committee members, composed of practicing physicians, clinical pharmacologists, compounding pharmacists, and patient

[04:49] advocates, took a different view. After reviewing extensive clinical data, published preclinical research, and hearing hours of public testimony from clinicians and patients, the panel voted, often by a narrow margin, to

[05:02] recommend six of the seven evaluated peptides. Let's look at the individual peptides that were considered. They were BPC 157, a 15 amino acid synthetic peptide derived from human

[05:17] gastric juices, evaluated for ulcerative colitis and inflammatory tissue repair. And I did a video on BPC 157, which is linked to above. KPV, a tripeptide fragment derived from alpha melanocyte stimulating hormone,

[05:33] evaluated for wound healing and gastrointestinal inflammation. TB 500, a synthetic derivative of thymosin beta 4, which plays a critical role in cellular migration and tissue regeneration.

[05:48] regeneration. Mots-c, a 16 amino acid mitochondrial derived peptide evaluated for metabolic regulation, insulin sensitivity, and osteoporosis. If you want to deep dive into Mots-c, we

[06:01] team that originally discovered the molecule, and that is also linked to above. Next with Semax, a synthetic hepato peptide modeled after a fragment of adrenocorticotropic

[06:15] hormone, studied for its cerebral ischemia, cognitive support, and nerve And the last approved peptide was Epitalon, a synthetic tetrapeptide modeled after the pineal bioregulator epithalamin, widely studied in longevity

[06:31] science for its role in cellular health and telomerase activation. was Emideltide, commonly known as delta sleep-inducing peptide or DSIP. The committee voted six to seven against

[06:46] recommendation, citing concerns regarding limited human clinical safety data, and its proposed use in sensitive applications such as opioid withdrawal. Throughout the hearings, committee members emphasized three compelling

[07:00] First, clinicians presented extensive real-world clinical experience demonstrating positive therapeutic outcomes in patients who had exhausted standard pharmaceutical treatments for chronic inflammatory bowel conditions,

[07:14] severe musculoskeletal injuries, and age-related tissue Second, the committee recognized the serious public health hazard created by categorical compounding bans. When regulated high-standard compounding

[07:28] pharmacies are prohibited from preparing therapeutic peptides, patient demand does not disappear. Instead, patients are driven to unregulated online vendors selling research chemicals that lack verified third-party testing, sterility

[07:44] verified third-party testing, sterility verification, and standardized dosing. The panel recognized that maintaining access through regulated compounding pharmacies provides a critical safety buffer for the public.

[07:59] synthetic peptides inherently carry a high degree of biocompatibility compared to small molecule synthetic drugs, and that existing pharmacopeial standards can effectively manage potential concerns regarding endotoxin levels,

[08:14] concerns regarding endotoxin levels, peptide purity, and sequence fidelity. While these advisory votes mark a victory for peptide medicine, it's vital to understand what happens next from a legal and practical standpoint.

[08:27] First, the recommendations of the PCAC are not binding. The FDA is not legally required to follow the committee's advice, although the agency historically adopts the panel's recommendations in the vast majority of cases.

[08:43] Second, for these six peptides to be permanently codified into section 503A bulk drug substances positive list, the FDA must complete formal notice and comment rulemaking. This administrative process requires

[08:58] publishing a proposed rule in the Federal Register, opening a public comment period, and issuing a final rule, a timeline that typically spans 8 to 12 months. In the interim, medical associations,

[09:12] telehealth networks, and compounding pharmacy alliances are actively petitioning the Department of Health and Human Services and the FDA to immediately reclassify these six recommended peptides into category 1.

[09:26] If placed in category 1, the FDA would exercise enforcement discretion, allowing compounding pharmacies to legally resume preparing these customized prescriptions right away while the formal rule making progresses.

[09:41] For patients and practitioners, this development signals a welcome return towards transparent physician-supervised access to promising regenerative molecules. As this regulatory process moves

[09:54] forward, the primary focus will center on ensuring rigorous manufacturing quality, pharmaceutical grade purity, and encouraging formal clinical trials and encouraging formal clinical trials to validate long-term efficacy.

[10:06] Now we want to hear from you. Have you used therapeutic peptides like BPC 157 or MOTS-c? And what are your thoughts on the FDA advisory committee's historic Let me know in the comments. Thank you for your attention, and I wish you all

[10:21] for your attention, and I wish you all well.